Bioresponsive Drug Delivery
随生理信号响应的智能递药体系
Zhen Gu（顾臻）
ABSRACT
Spurred by recent advances in materials chemistry, molecular pharmaceutics and nanobiotechnology, stimuli-responsive “smart” systems offer opportunities for precisely delivering drugs in dose-, spatial- and temporal-controlled manners. In this talk, I will discuss our ongoing efforts in developing physiological signal-triggered bioinspired drug delivery systems. I will first present the glucose-responsive synthetic systems for biomimetic delivery of insulin for diabetes treatment. Development of smart insulin patches will be emphasized. I will further discuss the local and targeted delivery of immunomodulatory therapeutics for treating cancer and infectious diseases. Our latest studies utilizing platelets, cell conjugates and sprayed gels for delivery of immune checkpoint inhibitors will be specifically introduced.
伴随着材料化学，分子药物学及纳米生物技术等相关领域的日新月异，受刺激而响应的可编程智能体系为在剂量、时空等尺度上实现精准的药物递送提供了可能。在本次报告中，我将介绍课题组目前在能随疾病相关生理信号触发的智能药物递送体系方面的创新与转化。首先，我将讨论能随血糖响应的仿生递送胰岛素方向上的一些进展，特别注重介绍“智能胰岛素贴片”的研发以及微针递药体系多样化的应用；另一方面，我将会介绍免疫治疗调节药物的局部和靶向递送，用于增强癌症治疗及降低细胞因子风暴，将着重介绍基于血小板、脂肪细胞和可喷涂凝胶的一些新型制剂的研发。
BIOGRAPHY
Dr. Zhen Gu is a Professor in the Department of Bioengineering and Director of the NIH Biotechnology Training in Biomedical Sciences and Engineering Program at the University of California, Los Angeles (UCLA). Dr. Gu received his B.S. degree in Chemistry and M.S. degree in Polymer Chemistry and Physics from Nanjing University. In 2010, he obtained Ph.D. from the Department of Chemical and Biomolecular Engineering at UCLA. He was a Postdoctoral Associate working with Dr. Robert Langer at MIT and Harvard Medical School during 2010 to 2012. Before he moved to UCLA in 2018, he had been appointed as a Jackson Family Distinguished Professor in the Joint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill and North Carolina State University. Dr. Gu’s group studies controlled drug delivery, biomaterials and cell therapy. He has published over 200 research papers and applied over 80 patents. He is a co-founder of five start-up companies, including Zenomics and ZenCapsule. Dr. Gu serves as an Associate Editor for Science Advances and Nano Research. He was also an Inaugural Chair of the Bioinspired and Biomimetic Delivery (BBD) Focus Group in the Controlled Release Society (CRS). He is the recipient of the Felix Franks Medal of the Royal Society of Chemistry (2019), Small Young Innovator Award (2019), Biomaterials Science Lectureship Award (2018), Young Investigator Award of CRS (2017), Sloan Research Fellowship (2016) and Pathway Award of the American Diabetes Association (ADA, 2015). MIT Technology Review listed him in 2015 as one of the top innovators under the age of 35 (TR35). He was elected to the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE) in 2019.
顾臻，美国加州大学洛杉矶分校（UCLA）生物工程系教授、NIH生物技术/生物医学与工程培训项目主任。本科、硕士毕业于南京大学化学系及高分子科学与工程系；2010年于UCLA获得工学博士学位；同年博士后获聘于麻省理工学院化工系/Koch癌症综合研究院、哈佛大学医学院，师从Robert Langer教授。2018年前任教于北卡罗莱纳大学教堂山分校/北卡州立大学联合生物医学工程系，领导药剂工程学科建设，创建了生物医学工程“创新转化学位”，以促进生物医药技术转化人才的培养，2018年获评Jackson Family杰出讲席正教授。其指导的“iMedication-智能医药实验室”研究方向包括蛋白质递药系统、生理响应材料、免疫治疗制剂、细胞治疗策略等。目前已发表学术论文200余篇，申请专利80余项。顾臻教授曾获“斯隆研究奖”、英国皇家化学会Felix Franks奖章、国际药物控释学会（CRS）“青年学者奖”、Small青年科学家创新奖、美国糖尿病学会（ADA）“青年教授奖”及“Pathway”研究奖、美国生物医学工程学会（BMES）“细胞/分子生物工程创新者奖”等。《麻省理工科技评论》曾将其评为“TR35全球杰出创新者”。2019年当选美国医学与生物工程院Fellow。其课题组首次报道了“智能胰岛素贴片”（Smart Insulin Patch）的原型并推动其临床转化，相关研究图片曾入选《科学》杂志年度十大科技图片。顾臻教授目前担任《Science Advances》及《Nano Research》副主编。